Specific considerations in the treatment of pediatric inflammatory bowel disease

References

• Loftus CG, Loftus EV Jr, Harmsen WS et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm. Bowel Dis.13(3), 254–261 (2007).
   PubMed Web of Science ®Google Scholar
• Kucharzik T, Maaser C, Lugering A et al. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm. Bowel Dis.12(11), 1068–1083 (2006).
   PubMed Web of Science ®Google Scholar
• Mamula P, Markowitz JE, Baldassano RN. Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol. Clin. North Am.32(3), 967–995 (2003).
   PubMed Web of Science ®Google Scholar
• Heyman MB, Kirschner BS, Gold BD et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J. Pediatr.146(1), 35–40 (2005).
   PubMed Web of Science ®Google Scholar
• Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature411(6837), 599–603 (2001).
   PubMed Web of Science ®Google Scholar
• Alvarez-Lobos M, Arostegui JI, Sans M et al. Crohn’s disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann. Surg.242(5), 693–700 (2005).
   PubMed Web of Science ®Google Scholar
• Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science314(5804), 1461–1463 (2006).
   PubMed Web of Science ®Google Scholar
• Tremelling M, Cummings F, Fisher SA et al. IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology132(5), 1657–1664 (2007).
   PubMed Web of Science ®Google Scholar
• Hampe J, Franke A, Rosenstiel P et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet.39(2), 207–211 (2007).
   PubMed Web of Science ®Google Scholar
• Prescott NJ, Fisher SA, Franke A et al. A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn’s disease and is independent of CARD15 and IBD5. Gastroenterology132(5), 1665–1671 (2007).
   PubMed Web of Science ®Google Scholar
• Jacobsen BA, Fallingborg J, Rasmussen HH et al. Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978–2002. Eur. J. Gastroenterol. Hepatol.18(6), 601–606 (2006).
   PubMed Web of Science ®Google Scholar
• Armitage E, Drummond HE, Wilson DC, Ghosh S. Increasing incidence of both juvenile-onset Crohn’s disease and ulcerative colitis in Scotland. Eur. J. Gastroenterol. Hepatol.13(12), 1439–1447 (2001).
   PubMed Web of Science ®Google Scholar
• Gower-Rousseau C, Salomez JL, Dupas JL et al. Incidence of inflammatory bowel disease in northern France (1988–1990). Gut35(10), 1433–1438 (1994).
   PubMed Web of Science ®Google Scholar
• Sawczenko A, Sandhu BK, Logan RF et al. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet357(9262), 1093–1094 (2001).
   PubMed Web of Science ®Google Scholar
• Kugathasan S, Judd RH, Hoffmann RG et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J. Pediatr.143(4), 525–531 (2003).
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Rifas-Shiman SL, Kleinman K et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin. Gastroenterol. Hepatol.5(12), 1424–1429 (2007).
   PubMed Web of Science ®Google Scholar
• Mamula P, Telega GW, Markowitz JE et al. Inflammatory bowel disease in children 5 years of age and younger. Am. J. Gastroenterol.97(8), 2005–2010 (2002).
   PubMed Web of Science ®Google Scholar
• Levine A, Karban A, Eliakim R et al. A polymorphism in the TNF-α promoter gene is associated with pediatric onset and colonic location of Crohn’s disease. Am. J. Gastroenterol.100(2), 407–413 (2005).
   PubMedGoogle Scholar
• Meinzer U, Idestrom M, Alberti C et al. Ileal involvement is age dependent in pediatric Crohn’s disease. Inflamm. Bowel Dis.11(7), 639–644 (2005).
   PubMed Web of Science ®Google Scholar
• Levine A, Kugathasan S, Annese V et al. Pediatric onset Crohn’s colitis is characterized by genotype-dependent age-related susceptibility. Inflamm. Bowel Dis.13(12), 1509–1515 (2007).
   PubMed Web of Science ®Google Scholar
• Gupta N, Bostrom AG, Kirschner BS et al. Gender Differences in presentation and course of disease in pediatric patients with Crohn disease. Pediatrics120(6), E1428–E1425 (2007).
   Google Scholar
• Turner D, Walsh CM, Benchimol EI et al. Severe paediatric ulcerative colitis: incidence, outcomes, and optimal timing for second line therapy. Gut (2007) (Epub ahead of print).
   Google Scholar
• Urlep D, Mamula P, Baldassano R. Extraintestinal manifestations of inflammatory bowel disease. Minerva Gastroenterol. Dietol.51(2), 147–163 (2005).
   PubMedGoogle Scholar
• Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology105(3), 681–691 (1993).
   PubMed Web of Science ®Google Scholar
• Newby EA, Sawczenko A, Thomas AG, Wilson D. Interventions for growth failure in childhood Crohn’s disease. Cochrane Database Syst. Rev.3, CD003873 (2005).
   Google Scholar
• Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn’s disease. Gastroenterology95(6), 1523–1527 (1988).
   PubMed Web of Science ®Google Scholar
• Sentongo TA, Semeao EJ, Piccoli DA, Stallings VA, Zemel BS. Growth, body composition, and nutritional status in children and adolescents with Crohn’s disease. J. Pediatr. Gastroenterol. Nutr.31(1), 33–40 (2000).
   PubMed Web of Science ®Google Scholar
• Hait E, Bousvaros A, Grand R. Pediatric inflammatory bowel disease: what children can teach adults. Inflamm. Bowel Dis.11(6), 519–527 (2005).
   PubMed Web of Science ®Google Scholar
• Leonard MB. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatrics119(Suppl. 2), S166–S174 (2007).
   Google Scholar
• De Benedetti F, Alonzi T, Moretta A et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J. Clin. Invest.99(4), 643–650 (1997).
   PubMed Web of Science ®Google Scholar
• Brown KA, Back SJ, Ruchelli ED et al. Lamina propria and circulating interleukin-6 in newly diagnosed pediatric inflammatory bowel disease patients. Am. J. Gastroenterol.97(10), 2603–2608 (2002).
   PubMed Web of Science ®Google Scholar
• Kim SC, Ferry GD. Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology126(6), 1550–1560 (2004).
   PubMed Web of Science ®Google Scholar
• Kirschner BS, Klich JR, Kalman SS, deFavaro MV, Rosenberg IH. Reversal of growth retardation in Crohn’s disease with therapy emphasizing oral nutritional restitution. Gastroenterology80(1), 10–15 (1981).
   PubMed Web of Science ®Google Scholar
• Gokhale R, Favus MJ, Karrison T et al. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology114(5), 902–911 (1998).
   PubMed Web of Science ®Google Scholar
• Semeao EJ, Jawad AF, Zemel BS et al. Bone mineral density in children and young adults with Crohn’s disease. Inflamm. Bowel Dis.5(3), 161–166 (1999).
   PubMed Web of Science ®Google Scholar
• Semeao EJ, Jawad AF, Stouffer NO et al. Risk factors for low bone mineral density in children and young adults with Crohn’s disease. J. Pediatr.135(5), 593–600 (1999).
   PubMed Web of Science ®Google Scholar
• Sylvester FA, Wyzga N, Hyams JS et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm. Bowel Dis.13(1), 42–50 (2007).
   PubMed Web of Science ®Google Scholar
• Burnham JM, Shults J, Semeao E et al. Body-composition alterations consistent with cachexia in children and young adults with Crohn disease. Am. J. Clin. Nutr.82(2), 413–420 (2005).
   PubMed Web of Science ®Google Scholar
• Sentongo TA, Semaeo EJ, Stettler N et al. Vitamin D status in children, adolescents, and young adults with Crohn disease. Am. J. Clin. Nutr.76(5), 1077–1081 (2002).
   PubMed Web of Science ®Google Scholar
• Franchimont N, Putzeys V, Collette J et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn’s disease. Aliment. Pharmacol. Ther.20(6), 607–614 (2004).
   PubMed Web of Science ®Google Scholar
• Ryan BM, Russel MG, Schurgers L et al. Effect of antitumour necrosis factor-α therapy on bone turnover in patients with active Crohn’s disease: a prospective study. Aliment. Pharmacol. Ther.20(8), 851–857 (2004).
   PubMedGoogle Scholar
• Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn’s disease. Am. J. Gastroenterol.100(9), 2031–2035 (2005).
   PubMedGoogle Scholar
• Thearle M, Horlick M, Bilezikian JP et al. Osteoporosis: an unusual presentation of childhood Crohn’s disease. J. Clin. Endocrinol. Metab.85(6), 2122–2126 (2000).
   PubMed Web of Science ®Google Scholar
• Belli DC, Seidman E, Bouthillier L et al. Chronic intermittent elemental diet improves growth failure in children with Crohn’s disease. Gastroenterology94(3), 603–610 (1988).
   PubMed Web of Science ®Google Scholar
• Fell JM, Paintin M, Arnaud-Battandier F et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn’s disease. Aliment. Pharmacol. Ther.14(3), 281–289 (2000).
   PubMed Web of Science ®Google Scholar
• Borrelli O, Cordischi L, Cirulli M et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a randomized controlled open-label trial. Clin. Gastroenterol. Hepatol.4(6), 744–753 (2006).
   PubMed Web of Science ®Google Scholar
• Afzal NA, Davies S, Paintin M et al. Colonic Crohn’s disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved. Dig. Dis. Sci.50(8), 1471–1475 (2005).
   PubMedGoogle Scholar
• Ludvigsson JF, Krantz M, Bodin L, Stenhammar L, Lindquist B. Elemental versus polymeric enteral nutrition in paediatric Crohn’s disease: a multicentre randomized controlled trial. Acta Paediatr.93(3), 327–335 (2004).
   PubMedGoogle Scholar
• Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev.1, CD000542 (2007).
   Google Scholar
• Day AS, Whitten KE, Lemberg DA et al. Exclusive enteral feeding as primary therapy for Crohn’s disease in Australian children and adolescents: a feasible and effective approach. J. Gastroenterol. Hepatol.21(10), 1609–1614 (2006).
   PubMed Web of Science ®Google Scholar
• Wilschanski M, Sherman P, Pencharz P et al. Supplementary enteral nutrition maintains remission in paediatric Crohn’s disease. Gut38(4), 543–548 (1996).
   PubMed Web of Science ®Google Scholar
• Berni Canani R, Terrin G, Borrelli O et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn’s disease. Dig. Liver Dis.38(6), 381–387 (2006).
   PubMedGoogle Scholar
• Johnson T, Macdonald S, Hill SM, Thomas A, Murphy MS. Treatment of active Crohn’s disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut55(3), 356–361 (2006).
   PubMed Web of Science ®Google Scholar
• Turner D, Zlotkin SH, Shah PS, Griffiths AM. Ω3 fatty acids (fish oil) for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev.2, CD006320 (2007).
   Google Scholar
• Romano C, Cucchiara S, Barabino A, Annese V, Sferlazzas C. Usefulness of Ω3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn’s disease: a double-blind, randomized, placebo-controlled study. World J. Gastroenterol.11(45), 7118–7121 (2005).
   PubMed Web of Science ®Google Scholar
• Bousvaros A, Guandalini S, Baldassano RN et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm. Bowel Dis.11(9), 833–839 (2005).
   PubMed Web of Science ®Google Scholar
• Van Gossum A, Dewit O, Louis E et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after lleo-caecal resection. Inflamm. Bowel Dis.13(2), 135–142 (2007).
   PubMed Web of Science ®Google Scholar
• Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology126(6), 1620–1633 (2004).
   PubMed Web of Science ®Google Scholar
• Lindsay JO, Whelan K, Stagg AJ et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn’s disease. Gut55(3), 348–355 (2006).
   PubMed Web of Science ®Google Scholar
• Turner D, Steinhart AH, Griffiths AM. Ω3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev.3, CD006443 (2007).
   Google Scholar
• Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet354(9179), 635–639 (1999).
   PubMed Web of Science ®Google Scholar
• Michail S, Sylvester F, Fuchs G, Issenman R. Clinical efficacy of probiotics: review of the evidence with focus on children. J. Pediatr. Gastroenterol. Nutr.43(4), 550–557 (2006).
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology119(2), 305–309 (2000).
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Helwig U et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology124(5), 1202–1209 (2003).
   PubMed Web of Science ®Google Scholar
• Sands BE. Therapy of inflammatory bowel disease. Gastroenterology118(2 Suppl. 1), S68–S82 (2000).
   PubMed Web of Science ®Google Scholar
• Markowitz J, Hyams J, Mack D et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn’s disease. Clin. Gastroenterol. Hepatol.4(9), 1124–1129 (2006).
   PubMed Web of Science ®Google Scholar
• Vermeire S, van Assche G, Rutgeerts P. Review article: Altering the natural history of Crohn’s disease – evidence for and against current therapies. Aliment. Pharmacol. Ther.25(1), 3–12 (2007).
   PubMed Web of Science ®Google Scholar
• Tung J, Loftus EV Jr, Freese DK et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn’s disease and ulcerative colitis. Inflamm. Bowel Dis.12(12), 1093–1100 (2006).
   PubMed Web of Science ®Google Scholar
• Bressler B, Sands BE. Review article: medical therapy for fistulizing Crohn’s disease. Aliment. Pharmacol. Ther.24(9), 1283–1293 (2006).
   PubMedGoogle Scholar
• Otley A, Steinhart AH. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev.4, CD000296 (2005).
   Google Scholar
• Escher JC. Budesonide versus prednisolone for the treatment of active Crohn’s disease in children: a randomized, double-blind, controlled, multicentre trial. Eur. J. Gastroenterol. Hepatol.16(1), 47–54 (2004).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Lofberg R, Feagan BG et al. Budesonide for maintenance of remission in patients with Crohn’s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am. J. Gastroenterol.100(8), 1780–1787 (2005).
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology Practice Parameters Committee. Am. J. Gastroenterol.99(7), 1371–1385 (2004).
   PubMed Web of Science ®Google Scholar
• Hyams J, Markowitz J, Lerer T et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin. Gastroenterol. Hepatol.4(9), 1118–1123 (2006).
   PubMed Web of Science ®Google Scholar
• Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin. Gastroenterol. Hepatol.5(1), 103–110 (2007).
   PubMed Web of Science ®Google Scholar
• Gross V, Bar-Meir S, Lavy A et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment. Pharmacol. Ther.23(2), 303–312 (2006).
   PubMed Web of Science ®Google Scholar
• Escher JC, Taminiau JA, Nieuwenhuis EE, Buller HA, Grand RJ. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm. Bowel Dis.9(1), 34–58 (2003).
   PubMedGoogle Scholar
• Zimmerman MJ, Jewell DP. Cytokines and mechanisms of action of glucocorticoids and aminosalicylates in the treatment of ulcerative colitis and Crohn’s disease. Aliment. Pharmacol. Ther.10(Suppl 2), 93–98 (1996).
   PubMedGoogle Scholar
• Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin. Gastroenterol. Hepatol.2(5), 379–388 (2004).
   PubMed Web of Science ®Google Scholar
• Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s Disease. Cochrane Database Syst. Rev.1, CD003715 (2005).
   Google Scholar
• Lochs H, Mayer M, Fleig WE et al. Prophylaxis of postoperative relapse in Crohn’s disease with mesalamine: European Cooperative Crohn’s Disease Study VI. Gastroenterology118(2), 264–273 (2000).
   PubMed Web of Science ®Google Scholar
• Lemann M. Review article: can post-operative recurrence in Crohn’s disease be prevented? Aliment. Pharmacol. Ther.24(Suppl. 3), 22–28 (2006).
   Google Scholar
• Griffiths A, Koletzko S, Sylvester F, Marcon M, Sherman P. Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn’s disease. J. Pediatr. Gastroenterol. Nutr.17(2), 186–192 (1993).
   PubMed Web of Science ®Google Scholar
• Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev.2, CD000544 (2006).
   Google Scholar
• Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev.2, CD000543 (2006).
   Google Scholar
• Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut40(6), 775–781 (1997).
   PubMed Web of Science ®Google Scholar
• Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am. J. Gastroenterol.95(5), 1263–1276 (2000).
   PubMed Web of Science ®Google Scholar
• Stange EF. Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease. Aliment. Pharmacol. Ther.24(Suppl. 3), 64–67 (2006).
   PubMedGoogle Scholar
• Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am. J. Gastroenterol.100(6), 1345–1353 (2005).
   PubMed Web of Science ®Google Scholar
• Ferry GD, Kirschner BS, Grand RJ et al. Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J. Pediatr. Gastroenterol. Nutr.17(1), 32–38 (1993).
   PubMedGoogle Scholar
• Kamm MA, Sandborn WJ, Gassull M et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology132(1), 66–75 (2007).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Kamm MA, Boddu P et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol.5(1), 95–102 (2007).
   PubMed Web of Science ®Google Scholar
• West RL, van der Woude CJ, Hansen BE et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn’s disease with infliximab: a double-blind placebo-controlled study. Aliment. Pharmacol. Ther.20(11–12), 1329–1336 (2004).
   PubMed Web of Science ®Google Scholar
• Perencevich M, Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm. Bowel Dis.12(7), 651–664 (2006).
   PubMed Web of Science ®Google Scholar
• Prantera C, Lochs H, Campieri M et al. Antibiotic treatment of Crohn’s disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment. Pharmacol. Ther.23(8), 1117–1125 (2006).
   PubMed Web of Science ®Google Scholar
• Markowitz J, Grancher K, Kohn N, Daum F. Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990–2000. Am. J. Gastroenterol.97(4), 928–932 (2002).
   PubMed Web of Science ®Google Scholar
• Jacobstein DA, Mamula P, Markowitz JE, Leonard M, Baldassano RN. Predictors of immunomodulator use as early therapy in pediatric Crohn’s disease. J. Clin. Gastroenterol.40(2), 145–148 (2006).
   PubMedGoogle Scholar
• Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology130(4), 1047–1053 (2006).
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Lamothe S, Yang HY et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology118(4), 705–713 (2000).
   PubMed Web of Science ®Google Scholar
• Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin. Gastroenterol. Hepatol.2(9), 731–743 (2004).
   PubMed Web of Science ®Google Scholar
• Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment. Pharmacol. Ther.22(1), 1–16 (2005).
   PubMed Web of Science ®Google Scholar
• Sandborn W, Sutherland L, Pearson D et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst. Rev.2, CD000545 (2000).
   Google Scholar
• Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst. Rev.2, CD000067 (2000).
   Google Scholar
• Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology119(4), 895–902 (2000).
   PubMed Web of Science ®Google Scholar
• Jeshion WC, Larsen KL, Jawad AF et al. Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn’s disease in children. J. Clin. Gastroenterol.30(3), 294–298 (2000).
   PubMedGoogle Scholar
• Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev.1, CD000478 (2007).
   PubMedGoogle Scholar
• Kader HA, Mascarenhas MR, Piccoli DA, Stouffer NO, Baldassano RN. Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J. Pediatr. Gastroenterol. Nutr.28(1), 54–58 (1999).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am. J. Gastroenterol.91(3), 423–433 (1996).
   PubMed Web of Science ®Google Scholar
• Grossman AB, Noble AJ, Baldassano RN. Increased dosing requirements of 6-MP and azathioprine for inflammatory bowel disease patients six years old and younger. Gastroenterology132(4 Suppl. S1), A443–A444 (2007).
   Google Scholar
• Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann. Intern. Med.111(8), 641–649 (1989).
   PubMed Web of Science ®Google Scholar
• Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology115(4), 813–821 (1998).
   PubMed Web of Science ®Google Scholar
• Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut54(8), 1121–1125 (2005).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Alfadhli A. Methotrexate in inflammatory bowel disease. Gastroenterol. Clin. North Am.33(2), 407–420 (2004).
   PubMed Web of Science ®Google Scholar
• Morgan SL, Baggott JE, Vaughn WH et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann. Intern. Med.121(11), 833–841 (1994).
   PubMed Web of Science ®Google Scholar
• Ravikumara M, Hinsberger A, Spray CH. Role of methotrexate in the management of Crohn disease. J. Pediatr. Gastroenterol. Nutr.44(4), 427–430 (2007).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rochon J, Fedorak RN et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N. Engl. J. Med.332(5), 292–297 (1995).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Fedorak RN, Irvine EJ et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N. Engl. J. Med.342(22), 1627–1632 (2000).
   PubMed Web of Science ®Google Scholar
• Uhlen S, Belbouab R, Narebski K et al. Efficacy of methotrexate in pediatric Crohn’s disease: a French multicenter study. Inflamm. Bowel Dis.12(11), 1053–1057 (2006).
   PubMed Web of Science ®Google Scholar
• Turner D, Grossman AB, Rosh J et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn’s disease. Am. J. Gastroenterol.102(12), 2804–2812 (2007).
   PubMed Web of Science ®Google Scholar
• Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol.12(11), 1227–1233 (2000).
   PubMed Web of Science ®Google Scholar
• Oren R, Arber N, Odes S et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology110(5), 1416–1421 (1996).
   PubMed Web of Science ®Google Scholar
• Cummings JR, Herrlinger KR, Travis SP et al. Oral methotrexate in ulcerative colitis. Aliment. Pharmacol. Ther.21(4), 385–389 (2005).
   PubMed Web of Science ®Google Scholar
• Paoluzi OA, Pica R, Marcheggiano A et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment. Pharmacol. Ther.16(10), 1751–1759 (2002).
   PubMed Web of Science ®Google Scholar
• Te HS, Schiano TD, Kuan SF et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am. J. Gastroenterol.95(11), 3150–3156 (2000).
   PubMed Web of Science ®Google Scholar
• Mack DR, Young R, Kaufman SS, Ramey L, Vanderhoof JA. Methotrexate in patients with Crohn’s disease after 6-mercaptopurine. J. Pediatr.132(5), 830–835 (1998).
   PubMed Web of Science ®Google Scholar
• Stephens MC, Baldassano RN, York A et al. The bioavailability of oral methotrexate in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr.40(4), 445–449 (2005).
   PubMed Web of Science ®Google Scholar
• Sun JH, Das KM. Low-dose oral methotrexate for maintaining Crohn’s disease remission: where we stand. J. Clin. Gastroenterol.39(9), 751–756 (2005).
   PubMedGoogle Scholar
• Rufo PA, Bousvaros A. Current therapy of inflammatory bowel disease in children. Paediatr. Drugs8(5), 279–302 (2006).
   PubMedGoogle Scholar
• McDonald JW, Feagan BG, Jewell D et al. Cyclosporine for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev.2, CD000297 (2005).
   Google Scholar
• Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology130(3), 940–987 (2006).
   PubMed Web of Science ®Google Scholar
• Mahdi G, Israel DM, Hassall E. Cyclosporine and 6-mercaptopurine for active, refractory Crohn’s colitis in children. Am. J. Gastroenterol.91(7), 1355–1359 (1996).
   PubMedGoogle Scholar
• Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med.330(26), 1841–1845 (1994).
   PubMed Web of Science ®Google Scholar
• Van Assche G, D’Haens G, Noman M et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology125(4), 1025–1031 (2003).
   PubMed Web of Science ®Google Scholar
• Ramakrishna J, Langhans N, Calenda K, Grand RJ, Verhave M. Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr.22(3), 296–302 (1996).
   PubMed Web of Science ®Google Scholar
• Treem WR, Cohen J, Davis PM, Justinich CJ, Hyams JS. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis. Colon Rectum38(5), 474–479 (1995).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Lama Y, Gisbert JP, Mate J. The role of tacrolimus in inflammatory bowel disease: a systematic review. Dig. Dis. Sci.51(10), 1833–1840 (2006).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Lama Y, Abreu L, Vera MI et al. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn’s disease: a pilot study. Inflamm. Bowel Dis.11(1), 8–15 (2005).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Present DH, Isaacs KL et al. Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology125(2), 380–388 (2003).
   PubMed Web of Science ®Google Scholar
• Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn’s disease: exploratory randomized controlled trial. Inflamm. Bowel Dis.13(3), 245–253 (2007).
   PubMed Web of Science ®Google Scholar
• Bousvaros A, Kirschner BS, Werlin SL et al. Oral tacrolimus treatment of severe colitis in children. J. Pediatr.137(6), 794–799 (2000).
   PubMed Web of Science ®Google Scholar
• Ziring DA, Wu SS, Mow WS et al. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J. Pediatr. Gastroenterol. Nutr.45(3), 306–311 (2007).
   PubMedGoogle Scholar
• Breese EJ, Michie CA, Nicholls SW et al. Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology106(6), 1455–1466 (1994).
   PubMed Web of Science ®Google Scholar
• Nicholls S, Stephens S, Braegger CP, Walker-Smith JA, MacDonald TT. Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J. Clin. Pathol.46(8), 757–760 (1993).
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs, 65(16), 2253–2286 (2005).
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med.337(15), 1029–1035 (1997).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet359(9317), 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med.340(18), 1398–1405 (1999).
   PubMed Web of Science ®Google Scholar
• Akobeng AK, Zachos M. Tumor necrosis factor-α antibody for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev.1, CD003574 (2004).
   Google Scholar
• Baldassano R, Braegger CP, Escher JC et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn’s disease. Am. J. Gastroenterol.94(4), 833–838 (2003).
   Google Scholar
• Cezard JP, Nouaili N, Talbotec C et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease. J. Pediatr. Gastroenterol. Nutr.36(5), 632–636 (2003).
   PubMed Web of Science ®Google Scholar
• Kugathasan S. Prolonged duration of response to infliximab in early pediatric Crohn’s disease. J. Pediatr. Gastroenterol. Nutr.33(Suppl. 1), S40–S43 (2001).
   Google Scholar
• Hyams J, Crandall W, Kugathasan S et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology132(3), 863–873 (2007).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med.353(23), 2462–2476 (2005).
   PubMed Web of Science ®Google Scholar
• Jarnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology128(7), 1805–1811 (2005).
   PubMed Web of Science ®Google Scholar
• Mamula P, Markowitz JE, Cohen LJ, von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: two-year follow-up. J. Pediatr. Gastroenterol. Nutr.38(3), 298–301 (2004).
   PubMed Web of Science ®Google Scholar
• Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm. Bowel Dis.11(3), 213–218 (2005).
   PubMed Web of Science ®Google Scholar
• Fanjiang G, Russell GH, Katz AJ. Short-and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. J. Pediatr. Gastroenterol. Nutr.44(3), 312–317 (2007).
   PubMed Web of Science ®Google Scholar
• Jacobstein DA, Markowitz JE, Kirschner BS et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm. Bowel Dis.11(5), 442–446 (2005).
   PubMed Web of Science ®Google Scholar
• Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin. Gastroenterol. Hepatol.4(10), 1248–1254 (2006).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin. Gastroenterol. Hepatol.2(7), 542–553 (2004).
   PubMed Web of Science ®Google Scholar
• Rampton DS. Preventing TB in patients with Crohn’s disease needing infliximab or other anti-TNF therapy. Gut54(10), 1360–1362 (2005).
   PubMedGoogle Scholar
• Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin. Gastroenterol. Hepatol.4(5), 621–630 (2006).
   PubMed Web of Science ®Google Scholar
• Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm. Bowel Dis.13(8), 1024–1030 (2007).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology130(2), 323–333 (2006).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology132(1), 52–65 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts PJ et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut56, 1232–1239 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med.146(12), 829–838 (2007).
   PubMed Web of Science ®Google Scholar
• Mian S, Baron H. Adalimumab, a novel anti-tumor necrosis factor-α antibody in a child with refractory Crohn’s disease. J. Pediatr. Gastroenterol. Nutr.41(3), 357–359 (2005).
   PubMedGoogle Scholar
• Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J. Gastroenterol.13(16), 2328–2332 (2007).
   PubMed Web of Science ®Google Scholar
• Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn’s disease. N. Engl. J. Med.348(1), 24–32 (2003).
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology132(5), 1672–1683 (2007).
   PubMed Web of Science ®Google Scholar
• MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev.1, CD006097 (2007).
   Google Scholar
• Sandborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med.353(18), 1912–1925 (2005).
   PubMed Web of Science ®Google Scholar
• Hyams JS, Wilson DC, Thomas A et al. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J. Pediatr. Gastroenterol. Nutr.44(2), 185–191 (2007).
   PubMed Web of Science ®Google Scholar
• Gordon FH, Hamilton MI, Donoghue S et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to α-4 integrin. Aliment. Pharmacol. Ther.16(4), 699–705 (2002).
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β-1a for multiple sclerosis. N. Engl. J. Med.353(4), 369–374 (2005).
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med.353(4), 375–381 (2005).
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med.353(4), 362–368 (2005).
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med.354(9), 924–933 (2006).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Rutgeerts P, Fedorak RN et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology129(3), 807–818 (2005).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn’s disease. N. Engl. J. Med.357(3), 228–238 (2007).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Engl. J. Med.357(3), 239–250 (2007).
   PubMed Web of Science ®Google Scholar